1197810-60-8
Chemical Structure
GLP-1 moiety from Dulaglutide
Synonym(s): [Gly8,36,Glu22]-GLP-1 (7-37)
- CAS No.: 1197810-60-8
- Formula:C149H221N37O49
- Molecular Weight:3314.62
SMILES: O=C(NCC(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(N[C@@H](CC4=CNC5=CC=CC=C45)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(NCC(NCC(NCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC6=CNC=N6)N
Biological Activity: GLP-1 moiety from Dulaglutide ([Gly8,36,Glu22]-GLP-1 (7-37)) is a 31-amino acid fragment derived from Dulaglutide (HY-P0120). GLP-1 moiety from Dulaglutide is a DPP-4-modified GLP-1 analog carrying the [Gly8,36,Glu22] sequence mutation, which acts as a GLP-1 receptor agonist. GLP-1 moiety from Dulaglutide covalently links to the human IgG4 Fc fragment and constitutes a part of the dulaglutide recombinant fusion protein. GLP-1 moiety from Dulaglutide exhibits glucose-dependent insulinotropic activity. GLP-1 moiety from Dulaglutide can be used in research related to type 2 diabetes[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GLP-1 moiety from Dulaglutide | 99.60% | GLP-1 moiety from Dulaglutide ([Gly8,36,Glu22]-GLP-1 (7-37)) is a 31-amino acid fragment derived from Dulaglutide (HY-P0120). GLP-1 moiety from Dulaglutide is a DPP-4-modified GLP-1 analog carrying the [Gly8,36,Glu22] sequence mutation, which acts as a GLP-1 receptor agonist. GLP-1 moiety from Dulaglutide covalently links to the human IgG4 Fc fragment and constitutes a part of the dulaglutide recombinant fusion protein. GLP-1 moiety from Dulaglutide exhibits glucose-dependent insulinotropic activity. GLP-1 moiety from Dulaglutide can be used in research related to type 2 diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Celeste A, et al. Anti-PCSK9-GLP-1 fusions and methods for use. US20160369010 A1. 2016 Dec 22.
- [2]. Xi L, et al. Dulaglutide accelerates diabetic wound healing by suppressing Nrf2-dependent ferroptosis in diabetic mice. Peptides. 2025 Mar;185:171366. [Content Brief]
- [3]. Wang R, et al. Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes. ACS omega. 2021 Mar 30;6(12):8271-8278. [Content Brief]
- [4]. Jimenez-Solem E, et al. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Current opinion in molecular therapeutics. 2010 Dec;12(6):790-7. [Content Brief]
- [5]. Lorenz M, et al. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorganic & medicinal chemistry letters. 2013 Jul 15;23(14):4011-8. [Content Brief]
